NAS:XFOR (USA)

X4 Pharmaceuticals Inc

$ 12.5 0 (-0.32%)
Volume: 8,832 Avg Vol (1m): 30,182
Market Cap $: 155.38 Mil Enterprise Value $: 94.33 Mil
P/E (TTM): 0.00 P/B: 1.71
Earnings Power Value 0
Net Current Asset Value 4.5
Tangible Book 4.87
Projected FCF 0
Median P/S Value 16.26
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.10
Cash-To-Debt range over the past 10 years
Min: 0.2, Med: 3.45, Max: 6.28
Current: 3.1
0.2
6.28
Debt-to-Equity 0.30
Debt-to-Equity range over the past 10 years
Min: -0.27, Med: 0.3, Max: 1.08
Current: 0.3
-0.27
1.08
Debt-to-EBITDA -0.68
Debt-to-EBITDA range over the past 10 years
Min: -0.76, Med: -0.48, Max: -0.19
Current: -0.68
-0.76
-0.19
Altman Z-Score 1.12
DISTRESS
GREY
SAFE

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1255.80
Operating Margin range over the past 10 years
Min: -1255.8, Med: -1220.17, Max: -1220.17
Current: -1255.8
-1255.8
-1220.17
Net Margin % -1271.83
Net Margin range over the past 10 years
Min: -1271.83, Med: -1229.17, Max: -1229.17
Current: -1271.83
-1271.83
-1229.17
ROE % -105.95
ROE range over the past 10 years
Min: -3162.8, Med: -1634.97, Max: -105.95
Current: -105.95
-3162.8
-105.95
ROA % -66.40
ROA range over the past 10 years
Min: -268.49, Med: -107.62, Max: -66.4
Current: -66.4
-268.49
-66.4
ROC (Joel Greenblatt) % -5859.40
ROC (Joel Greenblatt) range over the past 10 years
Min: -11892.92, Med: -4982.45, Max: -1677.11
Current: -5859.4
-11892.92
-1677.11
3-Year Total EBITDA Growth Rate -50.10
N/A
3-Year EPS w/o NRI Growth Rate -8.20
N/A

Ratios

Current vs industry vs history
PB Ratio 1.71
PB Ratio range over the past 10 years
Min: 0.73, Med: 1.68, Max: 2.48
Current: 1.71
0.73
2.48
PS Ratio 8.52
PS Ratio range over the past 10 years
Min: 7.57, Med: 11.09, Max: 15.3
Current: 8.52
7.57
15.3
EV-to-EBIT -2.24
EV-to-EBIT range over the past 10 years
Min: -3.3, Med: -0.8, Max: -0.3
Current: -2.24
-3.3
-0.3
EV-to-EBITDA -2.25
EV-to-EBITDA range over the past 10 years
Min: -3.3, Med: -0.8, Max: -0.3
Current: -2.25
-3.3
-0.3
EV-to-Revenue 26.95
EV-to-Revenue range over the past 10 years
Min: 3.2, Med: 8.3, Max: 40.9
Current: 26.95
3.2
40.9
Current Ratio 7.32
Current Ratio range over the past 10 years
Min: 0.47, Med: 5.31, Max: 7.45
Current: 7.32
0.47
7.45
Quick Ratio 7.32
Quick Ratio range over the past 10 years
Min: 0.47, Med: 5.31, Max: 7.45
Current: 7.32
0.47
7.45
Days Sales Outstanding 161.85
Days Sales Outstanding range over the past 10 years
Min: 0, Med: 0, Max: 161.85
Current: 161.85
0
161.85

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -37.00
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.57
Price-to-Tangible-Book range over the past 10 years
Min: 0.26, Med: 1.54, Max: 6.76
Current: 2.57
0.26
6.76
Price-to-Median-PS-Value 0.77
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 0.94, Max: 1.04
Current: 0.77
0
1.04
Earnings Yield (Joel Greenblatt) % -44.64
Earnings Yield (Greenblatt) range over the past 10 years
Min: -325, Med: -124.2, Max: -30.1
Current: -44.64
-325
-30.1

» XFOR's 30-Y Financials

Financials (Next Earnings Date: 2019-11-08)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XFOR

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare NYSE:KDMN WAR:MAB XKRX:053030 NAS:DERM TSE:2183 NAS:AVEO SHSE:603139 ASX:SPL NAS:MRUS NAS:QTRX XTER:FYB XKRX:174900 NAS:CRBP LSE:FARN SHSE:600556 XKRX:168330 ASX:VLA XBRU:CYAD HKSE:08158 XPAR:VLA
Traded in other countries
Address 890 Winter Street, Suite 230, Waltham, MA, USA, 02451
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.

More Statistics

Revenue (TTM) (Mil) $ 3.5
EPS (TTM) $ -20.29
Beta 0
Volatility % 209.2
52-Week Range $ 6.9 - 29.46
Shares Outstanding (Mil) 12.43

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N